Department of Nuclear Medicine, The First Affiliated Hospital of Soochow University, Suzhou, China.
Department of Nuclear Medicine, Changshu No. 2 People's Hospital, Changshu, China.
Biomed Res Int. 2020 Feb 25;2020:9746716. doi: 10.1155/2020/9746716. eCollection 2020.
In the present study, we aimed to investigate whether the metabolic parameters on baseline F-fluorodeoxyglucose positron emission tomography/computed tomography (F-FDG PET/CT) could be used to predict prognosis in peripheral T-cell lymphomas (PTCL).
A total of 51 nodal PTCL patients who underwent baseline F-FDG PET/CT were retrospectively evaluated in the present study. Total metabolic tumor volume (TMTV), total lesion glycolysis (TLG), and maximum standardized uptake value (SUV) were also assessed. Besides, the National Comprehensive Cancer Network International Prognostic Index (NCCN-IPI) was also included. Log-rank test and Cox regression analysis were used to evaluate progression-free survival (PFS) and overall survival (OS).
The median follow-up was 18 months. Patients with low TLG, TMTV, and SUV levels had a significantly better clinical outcome than those with high TLG, TMTV, and SUV levels. The 2-year PFS rates of the high- and low-TMTV groups were 34.62% and 80%, respectively ( < 0.001), whereas the corresponding 2-year OS rates were 46.15% and 84.00%, respectively ( < 0.001), whereas the corresponding 2-year OS rates were 46.15% and 84.00%, respectively ( < 0.001), whereas the corresponding 2-year OS rates were 46.15% and 84.00%, respectively ( < 0.001), whereas the corresponding 2-year OS rates were 46.15% and 84.00%, respectively ( < 0.001), whereas the corresponding 2-year OS rates were 46.15% and 84.00%, respectively ( < 0.001), whereas the corresponding 2-year OS rates were 46.15% and 84.00%, respectively ( < 0.001), whereas the corresponding 2-year OS rates were 46.15% and 84.00%, respectively ( < 0.001), whereas the corresponding 2-year OS rates were 46.15% and 84.00%, respectively ( < 0.001), whereas the corresponding 2-year OS rates were 46.15% and 84.00%, respectively ( < 0.001), whereas the corresponding 2-year OS rates were 46.15% and 84.00%, respectively ( < 0.001), whereas the corresponding 2-year OS rates were 46.15% and 84.00%, respectively ( < 0.001), whereas the corresponding 2-year OS rates were 46.15% and 84.00%, respectively ( = 10), intermediate-risk group with TMTV > 62.405 or NCCN-IPI score of 4-8 (2-year PFS and OS were 52.4% and 66.7%, respectively, = 10), intermediate-risk group with TMTV > 62.405 or NCCN-IPI score of 4-8 (2-year PFS and OS were 52.4% and 66.7%, respectively, = 10), intermediate-risk group with TMTV > 62.405 or NCCN-IPI score of 4-8 (2-year PFS and OS were 52.4% and 66.7%, respectively.
Baseline TMTV and TLG were independent predictors of PFS and OS in PTCL patients, and SUV and NCCN-IPI scores were also independent predictors of OS. Moreover, the combination of TMTV and NCCN-IPI scores improved patient risk-stratification at the initial stage and might contribute to the adjustment of the therapeutic regime. This trial is registered with ChiCTR1900025526.
本研究旨在探讨基线氟-18 氟代脱氧葡萄糖正电子发射断层扫描/计算机断层扫描（F-FDG PET/CT）的代谢参数是否可用于预测外周 T 细胞淋巴瘤（PTCL）的预后。
回顾性评估了 51 例接受基线 F-FDG PET/CT 的结内 PTCL 患者。还评估了总代谢肿瘤体积（TMTV）、总病灶糖酵解（TLG）和最大标准化摄取值（SUV）。此外，还包括国家综合癌症网络国际预后指数（NCCN-IPI）。采用对数秩检验和 Cox 回归分析评估无进展生存期（PFS）和总生存期（OS）。
中位随访时间为 18 个月。低 TLG、TMTV 和 SUV 水平的患者临床结局明显优于高 TLG、TMTV 和 SUV 水平的患者。高 TMTV 组和低 TMTV 组的 2 年 PFS 率分别为 34.62%和 80%（<0.001），相应的 2 年 OS 率分别为 46.15%和 84.00%（<0.001）。NCCN-IPI 评分为 0-2 分的低危组、高危组和中高危组的 2 年 PFS 率分别为 87.1%、38.5%和 52.4%（<0.001），相应的 2 年 OS 率分别为 91.3%、60.9%和 66.7%（<0.001）。此外，SUV 和 NCCN-IPI 评分也是 OS 的独立预测因素。此外，TMTV 和 NCCN-IPI 评分的组合可在初始阶段改善患者的风险分层，可能有助于调整治疗方案。本试验在中国临床试验注册中心注册，注册号为 ChiCTR1900025526。
